Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.00 Average Price Target from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus recommendation of “Hold” from the nine ratings firms that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

ZNTL has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a research report on Monday, August 12th. Finally, Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $3.61 on Friday. The stock has a 50-day simple moving average of $3.36 and a 200 day simple moving average of $4.82. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.07. The stock has a market capitalization of $257.27 million, a PE ratio of -1.45 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. As a group, equities research analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Decheng Capital LLC raised its stake in shares of Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. Verition Fund Management LLC raised its position in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after buying an additional 399,745 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after buying an additional 353,384 shares during the last quarter. Finally, Primecap Management Co. CA lifted its position in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after buying an additional 265,690 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.